Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Saved in:
| Title: | Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. |
|---|---|
| Authors: | Walter, Adam1 (AUTHOR), Rocconi, Rodney P.2 (AUTHOR), Monk, Bradley J.3 (AUTHOR), Herzog, Thomas J.4 (AUTHOR), Manning, Luisa5 (AUTHOR), Bognar, Ernest5 (AUTHOR), Wallraven, Gladice5 (AUTHOR), Aaron, Phylicia5 (AUTHOR), Horvath, Staci5 (AUTHOR), Tang, Min6 (AUTHOR), Stanbery, Laura5 (AUTHOR), Coleman, Robert L.7 (AUTHOR), Nemunaitis, John1,5 (AUTHOR) bmarr@gradalisinc.com |
| Source: | Gynecologic Oncology. Dec2021, Vol. 163 Issue 3, p459-464. 6p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
